{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:45:14Z","timestamp":1791942314718,"version":"4.3.4"},"reference-count":144,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Acute promyelocytic leukemia (APL) has a well-established mechanism and a long-term prognosis that exceeds that of any other acute leukemia. These improving outcomes are due, in part, to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), two targeted and highly active agents in this disease. However, there remains a considerable morbidity and mortality risk in APL secondary to clinically significant hemorrhagic and\/or thrombotic events. Prevention and treatment of these coagulopathic complications remain significant impediments to further progress in optimizing outcomes for patients with APL. Moreover, the relative rarity of APL hinders adequately powered randomized controlled trials for evaluating APL coagulopathy management strategies. This review draws from peer-reviewed works falling between initial descriptions of APL in 1957 and work published prior to January 2023 and provides an updated overview of the pathophysiology of hemorrhagic and thrombotic complications in APL, outlines risk stratification parameters, and compiles current clinical best practices. An improved understanding of the pathophysiologic mechanisms driving hemorrhage and thrombosis along with the completion of well-designed trials of management strategies will assist clinicians in developing interventions that mitigate these devastating complications in an otherwise largely curable disease.<\/jats:p>","DOI":"10.3390\/cancers15133477","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T01:38:32Z","timestamp":1688434712000},"page":"3477","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["The Coagulopathy of Acute Promyelocytic Leukemia: An Updated Review of Pathophysiology, Risk Stratification, and Clinical Management"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-9229","authenticated-orcid":false,"given":"Jack","family":"Hermsen","sequence":"first","affiliation":[{"name":"University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9105-698X","authenticated-orcid":false,"given":"Bryan","family":"Hambley","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, University of Cincinnati, 3125 Eden Ave, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer Statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1002\/cncr.27623","article-title":"Acute Promyelocytic Leukemia: A Population-Based Study on Incidence and Survival in the United States, 1975\u20132008","volume":"118","author":"Chen","year":"2012","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute Leukemia Incidence and Patient Survival among Children and Adults in the United States, 2001\u20132007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V48.1.9.9","article-title":"Acute Nonlymphocytic Leukemia in Adults: Correlations with Q-Banded Chromosomes","volume":"48","author":"Golomb","year":"1976","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12032-013-0478-y","article-title":"International Society of Thrombosis and Hemostasis Scoring System for Disseminated Intravascular Coagulation \u2265 6: A New Predictor of Hemorrhagic Early Death in Acute Promyelocytic Leukemia","volume":"30","author":"Mitrovic","year":"2013","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","article-title":"All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia","volume":"337","author":"Tallman","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia","volume":"369","author":"Avvisati","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3026(15)00115-5","article-title":"Use of Arsenic Trioxide in Remission Induction and Consolidation Therapy for Acute Promyelocytic Leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Study: A Non-Randomised Phase 2 Trial","volume":"2","author":"Iland","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/leu.2014.240","article-title":"Early Death in Acute Promyelocytic Leukemia (APL) in French Centers: A Multicenter Study in 399 Patients","volume":"28","author":"Thomas","year":"2014","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/leu.2017.71","article-title":"Early Death Rates Remain High in High-Risk APL: Update from the Swedish Acute Leukemia Registry 1997\u20132013","volume":"31","author":"Lehmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","article-title":"Early Death Rate in Acute Promyelocytic Leukemia Remains High despite All-Trans Retinoic Acid","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e9324","DOI":"10.1097\/MD.0000000000009324","article-title":"Analysis of Early Death in Newly Diagnosed Acute Promyelocytic Leukemia Patients","volume":"96","author":"Xu","year":"2017","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/08880018.2022.2082610","article-title":"Early Mortality Continues to Be a Barrier to Excellent Survival in Childhood Acute Promyelocytic Leukemia: A Retrospective Study of 62 Patients Spanning 17 Years","volume":"40","author":"Roy","year":"2023","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and Prognostic Factors of Remission Induction Failure in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Idarubicin","volume":"111","author":"Montesinos","year":"2008","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.thromres.2014.11.026","article-title":"Thrombotic Events in Acute Promyelocytic Leukemia","volume":"135","author":"Mitrovic","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.leu.2404377","article-title":"Occurrence of Thrombotic Events in Acute Promyelocytic Leukemia Correlates with Consistent Immunophenotypic and Molecular Features","volume":"21","author":"Breccia","year":"2007","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.thromres.2012.11.024","article-title":"Thrombosis in Acute Promyelocytic Leukemia","volume":"131","author":"Rashidi","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2141.2008.07323.x","article-title":"Virchow and His Triad: A Question of Attribution","volume":"143","author":"Bagot","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"722614","DOI":"10.3389\/fmed.2021.722614","article-title":"Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?","volume":"8","author":"Hambley","year":"2021","journal-title":"Front. Med."},{"key":"ref_21","first-page":"319","article-title":"Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis","volume":"11","author":"Periayah","year":"2017","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin Clot Structure and Function","volume":"31","author":"Undas","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.ATV.0000130465.23430.74","article-title":"Role of Tissue Factor in Hemostasis, Thrombosis, and Vascular Development","volume":"24","author":"Mackman","year":"2004","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1172\/JCI106680","article-title":"Functional Evaluation of an Inherited Abnormal Fibrinogen: Fibrinogen \u201cBaltimore\u201d","volume":"50","author":"Beck","year":"1971","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Brunclikova, M., Simurda, T., Zolkova, J., Sterankova, M., Skornova, I., Dobrotova, M., Kolkova, Z., Loderer, D., Grendar, M., and Hudecek, J. (2022). Heterogeneity of Genotype\u2013Phenotype in Congenital Hypofibrinogenemia\u2014A Review of Case Reports Associated with Bleeding and Thrombosis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041083"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa042991","article-title":"Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage","volume":"352","author":"Mayer","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ejh.13348","article-title":"The Many Roles of Tranexamic Acid: An Overview of the Clinical Indications for TXA in Medical and Surgical Patients","volume":"104","author":"Cai","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_28","first-page":"149","article-title":"Prothrombin Complex Concentrates: An Update","volume":"8","author":"Franchini","year":"2010","journal-title":"Blood Transfus."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2009-09-241851","article-title":"The New Oral Anticoagulants","volume":"115","author":"Garcia","year":"2010","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MOH.0000000000000221","article-title":"What\u2019s New in the Pathogenesis of the Coagulopathy in Acute Promyelocytic Leukemia?","volume":"23","author":"Mantha","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0002-9343(86)90617-0","article-title":"Acute Promyelocytic Leukemia: M.D. Anderson Hospital Experience","volume":"80","author":"Kantarjian","year":"1986","journal-title":"Am. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood.V73.5.1116.1116","article-title":"Acute Promyelocytic Leukemia: Treatment Results during a Decade at Memorial Hospital","volume":"73","author":"Cunningham","year":"1989","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0037-1963(01)90001-0","article-title":"Acute Promyelocytic Leukemia: Clinical and Morphologic Features and Prognostic Factors","volume":"38","author":"Awisati","year":"2001","journal-title":"Semin. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood.V75.11.2112.2112","article-title":"Early Deaths and Anti-Hemorrhagic Treatments in Acute Promyelocytic Leukemia. A GIMEMA Retrospective Study in 268 Consecutive Patients","volume":"75","author":"Rodeghiero","year":"1990","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.leukres.2010.05.022","article-title":"Significance of Fibrinogen, D-Dimer, and LDH Levels in Predicting the Risk of Bleeding in Patients with Acute Promyelocytic Leukemia","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1073\/pnas.0915006107","article-title":"PML\/RARalpha Fusion Protein Transactivates the Tissue Factor Promoter through a GAGC-Containing Element without Direct DNA Association","volume":"107","author":"Yan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V92.1.143.413k18_143_151","article-title":"Cancer Procoagulant and Tissue Factor Are Differently Modulated by All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells","volume":"92","author":"Falanga","year":"1998","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/blood.V84.9.3001.3001","article-title":"All-Trans Retinoic Acid Upregulates Thrombomodulin and Downregulates Tissue-Factor Expression in Acute Promyelocytic Leukemia Cells: Distinct Expression of Thrombomodulin and Tissue Factor in Human Leukemic Cells","volume":"84","author":"Koyama","year":"1994","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.beha.2008.12.007","article-title":"The Coagulopathy of Acute Promyelocytic Leukaemia Revisited","volume":"22","author":"Stein","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V63.4.965.965","article-title":"Liver Dysfunction Rather than Intravascular Coagulation as the Main Cause of Low Protein C and Antithrombin III in Acute Leukemia","volume":"63","author":"Rodeghiero","year":"1984","journal-title":"Blood"},{"key":"ref_41","first-page":"2","article-title":"Coagulation Disorders Associated with Acute Promyelocytic Leukemia: Corrective Effect of All-Trans Retinoic Acid Treatment","volume":"7","author":"Dombret","year":"1993","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0049-3848(88)90349-0","article-title":"Levels of Thrombin-Antithrombin III Complex in Plasma in Cases of Acute Promyelocytic Leukemia","volume":"50","author":"Asakura","year":"1988","journal-title":"Thromb. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2011.08922.x","article-title":"The Pathogenesis and Management of the Coagulopathy of Acute Promyelocytic Leukaemia","volume":"156","author":"Breen","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bjh.14255","article-title":"Bleeding Related to Disturbed Fibrinolysis","volume":"175","author":"Kolev","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Simurda, T., Vilar, R., Zolkova, J., Ceznerova, E., Kolkova, Z., Loderer, D., Neerman-Arbez, M., Casini, A., Brunclikova, M., and Skornova, I. (2020). A Novel Nonsense Mutation in FGB (c.1421G>A; p.Trp474Ter) in the Beta Chain of Fibrinogen Causing Hypofibrinogenemia with Bleeding Phenotype. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120605"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/jcp.49.12.958","article-title":"Hyperfibrinolysis","volume":"49","author":"Hunt","year":"1996","journal-title":"J. Clin. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/10245332.2018.1470069","article-title":"Characteristics of Fibrinolytic Disorders in Acute Promyelocytic Leukemia","volume":"23","author":"Wang","year":"2018","journal-title":"Hematology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJM199904013401303","article-title":"Annexin II and Bleeding in Acute Promyelocytic Leukemia","volume":"340","author":"Menell","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.leukres.2010.11.008","article-title":"The Expression of Annexin II and Its Role in the Fibrinolytic Activity in Acute Promyelocytic Leukemia","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21198","DOI":"10.1016\/S0021-9258(17)31948-8","article-title":"An Endothelial Cell Receptor for Plasminogen\/Tissue Plasminogen Activator (t-PA). II. Annexin II-Mediated Enhancement of t-PA-Dependent Plasminogen Activation","volume":"269","author":"Cesarman","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1538-7933.2004.00593.x","article-title":"Expression of Receptors for Plasminogen Activators on Endothelial Cell Surface Depends on Their Origin","volume":"2","author":"Kwaan","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.1989.tb06311.x","article-title":"The Bleeding Disorder in Acute Promyelocytic Leukaemia: Fibrinolysis Due to u-PA Rather than Defibrination","volume":"71","author":"Bennett","year":"1989","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/10245330310001621323","article-title":"Urokinase Plasminogen Activator Receptor and Soluble Matrix Metalloproteinase-9 in Acute Myeloid Leukemia Patients: A Possible Relation to Disease Invasion","volume":"8","author":"Aref","year":"2003","journal-title":"Hematology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.1988.tb02432.x","article-title":"Acquired Alpha-2-Antiplasmin Deficiency in Acute Promyelocytic Leukaemia","volume":"70","author":"Avvisati","year":"1988","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/bloodadvances.2022006980","article-title":"CD44\u2013Fibrinogen Binding Promotes Bleeding in Acute Promyelocytic Leukemia by in Situ Fibrin(Ogen) Deposition","volume":"6","author":"Wang","year":"2022","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.thromres.2010.12.008","article-title":"Degradation of Cross-Linked Fibrin by Leukocyte Elastase as Alternative Pathway for Plasmin-Mediated Fibrinolysis in Sepsis-Induced Disseminated Intravascular Coagulation","volume":"127","author":"Madoiwa","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1055\/s-0037-1613942","article-title":"Elastase Mediated Fibrinolysis in Acute Promyelocytic Leukemia","volume":"83","author":"Oudijk","year":"2000","journal-title":"Thromb. Haemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"117229","DOI":"10.1016\/j.lfs.2019.117229","article-title":"Neutrophil Elastase-Mediated Proteolysis of the Tumor Suppressor P200 CUX1 Promotes Cell Proliferation and Inhibits Cell Differentiation in APL","volume":"242","author":"Yu","year":"2020","journal-title":"Life Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/hs1201.99512","article-title":"Matrix Metalloproteinase Expression Is Related to Hemorrhagic Transformation after Cardioembolic Stroke","volume":"32","author":"Montaner","year":"2001","journal-title":"Stroke"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s13311-020-00839-0","article-title":"Matrix Metalloproteinases in Acute Intracerebral Hemorrhage","volume":"17","author":"Lattanzi","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.7314\/APJCP.2016.17.3.1519","article-title":"Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia","volume":"17","author":"Chaudhary","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.2147\/OTT.S144438","article-title":"Low Platelet Count Is Potentially the Most Important Contributor to Severe Bleeding in Patients Newly Diagnosed with Acute Promyelocytic Leukemia","volume":"10","author":"Song","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/j.1538-7836.2011.04506.x","article-title":"Differences in Platelet Function in Patients with Acute Myeloid Leukemia and Myelodysplasia Compared to Equally Thrombocytopenic Patients with Immune Thrombocytopenia","volume":"9","author":"Psaila","year":"2011","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bumbea, H., Vladareanu, A.M., Dumitru, I., Popov, V.M., Ciufu, C., Nicolescu, A., Onisai, M., Marinescu, C., Cisleanu, D., and Voican, I. (2021). Platelet Defects in Acute Myeloid Leukemia\u2014Potential for Hemorrhagic Events. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010118"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2011.78","article-title":"Continuing High Early Death Rate in Acute Promyelocytic Leukemia: A Population-Based Report from the Swedish Adult Acute Leukemia Registry","volume":"25","author":"Lehmann","year":"2011","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood.V79.3.543.543","article-title":"Reassessing the Hemostatic Disorder Associated With Acute Promyelocytic Leukemia","volume":"79","author":"Tallman","year":"1992","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B","article-title":"Acute Promyelocytic Leukemia in 57 Previously Untreated Patients","volume":"55","author":"Cordonnier","year":"1985","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clml.2019.09.616","article-title":"Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience","volume":"20","author":"Sobas","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2016-10-747170","article-title":"Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era","volume":"129","author":"Mantha","year":"2017","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E370","DOI":"10.1002\/ajh.25252","article-title":"Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia Treated in California","volume":"93","author":"Ho","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.clml.2018.11.004","article-title":"Real-Life Outcomes on Acute Promyelocytic Leukemia in Brazil\u2014Early Deaths Are Still a Problem","volume":"19","author":"Marquez","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.thromres.2021.12.020","article-title":"Predictive Factors for Differentiating Thrombohemorrhagic Disorders in High-Risk Acute Promyelocytic Leukemia","volume":"210","author":"Xiao","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdn755","article-title":"Prediction of Fatal Intracranial Hemorrhage in Patients with Acute Myeloid Leukemia","volume":"20","author":"Chen","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3324\/haematol.2011.046490","article-title":"Treatment Advances Have Not Improved the Early Death Rate in Acute Promyelocytic Leukemia","volume":"97","author":"McClellan","year":"2012","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"106356","DOI":"10.1016\/j.leukres.2020.106356","article-title":"Hemorrhage in Acute Promyelocytic Leukemia: Can It Be Predicted and Prevented?","volume":"94","author":"Naymagon","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0609.2006.00803.x","article-title":"Severe Hemorrhagic Complications during Remission Induction Therapy for Acute Promyelocytic Leukemia: Incidence, Risk Factors, and Influence on Outcome","volume":"78","author":"Yanada","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0609.2011.01747.x","article-title":"Clinical Bleeding Events and Laboratory Coagulation Profiles in Acute Promyelocytic Leukemia","volume":"88","author":"Chang","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3324\/haematol.2009.017962","article-title":"Early Hemorrhagic Death before Starting Therapy in Acute Promyelocytic Leukemia: Association with High WBC Count, Late Diagnosis and Delayed Treatment Initiation","volume":"95","author":"Breccia","year":"2010","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-017-3042-6","article-title":"Predictors of Thrombohemorrhagic Early Death in Children and Adolescents with t(15;17)-Positive Acute Promyelocytic Leukemia Treated with ATRA and Chemotherapy","volume":"96","author":"Abla","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.bcmd.2019.102351","article-title":"Factors Affecting Thrombohemorrhagic Early Death in Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide Alone","volume":"79","author":"Hou","year":"2019","journal-title":"Blood Cells. Mol. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e23750","DOI":"10.1002\/jcla.23750","article-title":"Procoagulant Platelets: Generation, Characteristics, and Therapeutic Target","volume":"35","author":"Chu","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1111\/jth.15074","article-title":"Management of Hemostatic Complications in Acute Leukemia: Guidance from the SSC of the ISTH","volume":"18","author":"Wang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood-2017-01-757930","article-title":"Laboratory Predictors of Bleeding and the Effect of Platelet and RBC Transfusions on Bleeding Outcomes in the PLADO Trial","volume":"130","author":"Uhl","year":"2017","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1080\/10428194.2019.1581187","article-title":"Predictors of Early Hemorrhage in Acute Promyelocytic Leukemia","volume":"60","author":"Naymagon","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.2147\/CMAR.S309138","article-title":"Absolute Circulating Leukemic Cells as a Risk Factor for Early Bleeding Events in Patients with Non-High-Risk Acute Promyelocytic Leukemia","volume":"13","author":"Pei","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00277-023-05122-8","article-title":"Value of the FDP\/FIB Ratio in Predicting Early Severe Bleeding Events in Patients with Newly Diagnosed Acute Promyelocytic Leukemia","volume":"102","author":"Li","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00277-020-04245-6","article-title":"Predictors of Early Death, Serious Hemorrhage, and Differentiation Syndrome in Japanese Patients with Acute Promyelocytic Leukemia","volume":"99","author":"Minamiguchi","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.V126.23.2278.2278","article-title":"Tissue Factor Pathway Inhibitor (TFPI) May Be Another Important Factor in the Coagulopathy in Acute Promyelocytic Leukemia (APL)","volume":"126","author":"Bassi","year":"2015","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/ATVBAHA.109.200964","article-title":"Tissue Factor\u2013Bearing Microparticles and Thrombus Formation","volume":"31","author":"Zwicker","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1055\/s-0030-1267045","article-title":"Role of Microparticles in the Hemostatic Dysfunction in Acute Promyelocytic Leukemia","volume":"36","author":"Kwaan","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1182\/blood.V122.21.3620.3620","article-title":"Thrombin Generationand Fibrinolytic Activity in Microparticles In Acute Promyelocytic Leukemia","volume":"122","author":"Kwaan","year":"2013","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00277-013-1676-6","article-title":"Increased Promyelocytic-Derived Microparticles: A Novel Potential Factor for Coagulopathy in Acute Promyelocytic Leukemia","volume":"92","author":"Ma","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00277-008-0446-3","article-title":"Tissue Factor Procoagulant Activity of Plasma Microparticles in Patients with Cancer-Associated Disseminated Intravascular Coagulation","volume":"87","author":"Langer","year":"2008","journal-title":"Ann. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.V70.4.1218.1218","article-title":"Secretion of Interleukin-1 by Acute Myeloblastic Leukemia Cells in Vitro Induces Endothelial Cells to Secrete Colony Stimulating Factors","volume":"70","author":"Griffin","year":"1987","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0002-9343(88)90420-2","article-title":"Potential Role of Interleukin-1 as the Trigger for Diffuse Intravascular Coagulation in Acute Nonlymphoblastic Leukemia","volume":"84","author":"Cozzolino","year":"1988","journal-title":"Am. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0038-1661661","article-title":"Interleukin 1 Stimulates Endothelial Cell Tissue Factor Production and Expression by a Prostaglandin-Independent Mechanism","volume":"56","author":"Schorer","year":"1986","journal-title":"Thromb. Haemost."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1016\/S0021-9258(18)60636-2","article-title":"Cytokine Activation of Vascular Endothelium. Effects on Tissue-Type Plasminogen Activator and Type 1 Plasminogen Activator Inhibitor","volume":"263","author":"Schleef","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.V77.3.542.542","article-title":"Regulation of Thrombomodulin by Tumor Necrosis Factor-Alpha: Comparison of Transcriptional and Posttranscriptional Mechanisms","volume":"77","author":"Lentz","year":"1991","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.leukres.2012.08.012","article-title":"Recombinant Human Soluble Thrombomodulin Safely and Effectively Rescues Acute Promyelocytic Leukemia Patients from Disseminated Intravascular Coagulation","volume":"36","author":"Ikezoe","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12185-013-1463-0","article-title":"Pathogenesis of Disseminated Intravascular Coagulation in Patients with Acute Promyelocytic Leukemia, and Its Treatment Using Recombinant Human Soluble Thrombomodulin","volume":"100","author":"Ikezoe","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2021.04.003","article-title":"Efficacy of Recombinant Human Soluble Thrombomodulin in Induction Therapy for Acute Promyelocytic Leukemia","volume":"202","author":"Matsuda","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.thromres.2014.02.025","article-title":"Thrombomodulin Alfa Treatment in Patients with Acute Promyelocytic Leukemia and Disseminated Intravascular Coagulation: A Retrospective Analysis of an Open-Label, Multicenter, Post-Marketing Surveillance Study Cohort","volume":"133","author":"Matsushita","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of Acute Promyelocytic Leukemia: Updated Recommendations from an Expert Panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1182\/blood.V108.11.1503.1503","article-title":"Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols","volume":"108","author":"Montesinos","year":"2006","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345833","article-title":"Acute Promyelocytic Leukemia-Associated Thrombosis","volume":"130","author":"Chang","year":"2013","journal-title":"Acta Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The Risk of Thrombosis in Patients with Acute Leukemia: Occurrence of Thrombosis at Diagnosis and during Treatment","volume":"3","author":"Rossi","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2019.02.007","article-title":"The Value of FDP\/FIB and D-Dimer\/FIB Ratios in Predicting High-Risk APL-Related Thrombosis","volume":"79","author":"Bai","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.blre.2014.07.001","article-title":"Acute Promyelocytic Leukemia: What Is the New Standard of Care?","volume":"28","author":"Watts","year":"2014","journal-title":"Blood Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","article-title":"Use of All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia","volume":"72","author":"Huang","year":"1988","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","article-title":"A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia","volume":"94","author":"Fenaux","year":"1999","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic Trioxide and All-Trans Retinoic Acid Treatment for Acute Promyelocytic Leukaemia in All Risk Groups (AML17): Results of a Randomised, Controlled, Phase 3 Trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2141.2005.05750.x","article-title":"All-Trans Retinoic Acid-Induced Downregulation of Annexin II Expression in Myeloid Leukaemia Cell Lines Is Not Confined to Acute Promyelocytic Leukaemia","volume":"131","author":"Olwill","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood.V86.9.3535.bloodjournal8693535","article-title":"Effect of All-Trans Retinoic Acid on Procoagulant and Fibrinolytic Activities of Cultured Blast Cells from Patients with Acute Promyelocytic Leukemia","volume":"86","author":"Teofili","year":"1995","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1538-7836.2004.00787.x","article-title":"Effects of All-Trans Retinoic Acid or Chemotherapy on the Molecular Regulation of Systemic Blood Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia","volume":"2","author":"Tallman","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood.V114.22.3986.3986","article-title":"Arsenic Trioxide (ATO) and All-Trans Retinoic Acid (ATRA) Differently Affect the Thrombin Generation Potential of Acute Promyelocytic Leukemia (APL) Cells","volume":"114","author":"Falanga","year":"2009","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wu, S., Luo, D., Zhou, J., and Li, D. (2016). Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147545"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral Arsenic plus Retinoic Acid versus Intravenous Arsenic plus Retinoic Acid for Non-High-Risk Acute Promyelocytic Leukaemia: A Non-Inferiority, Randomised Phase 3 Trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"pe25","DOI":"10.1126\/stke.121pe25","article-title":"ETosis: A Novel Cell Death Pathway","volume":"1","author":"Wartha","year":"2008","journal-title":"Sci. Signal."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e2283","DOI":"10.1038\/cddis.2016.186","article-title":"Extracellular DNA Traps Released by Acute Promyelocytic Leukemia Cells through Autophagy","volume":"7","author":"Ma","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41419-017-0018-3","article-title":"Arsenic Trioxide Promoting ETosis in Acute Promyelocytic Leukemia through MTOR-Regulated Autophagy","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, C., Zuo, N., Yang, H., Fang, S., and Shi, J. (2022). Extracellular Traps Increase Burden of Bleeding by Damaging Endothelial Cell in Acute Promyelocytic Leukaemia. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.841445"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA Traps Promote Thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood-2016-05-718114","article-title":"The Role of Leukocytes in Thrombosis","volume":"128","author":"Swystun","year":"2016","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute Promyelocytic Leukemia Current Treatment Algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective Treatment of Acute Promyelocytic Leukemia with All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-Term Outcome of Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/bloodadvances.2019001278","article-title":"A Phase 2 Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Patients with High-Risk APL (SWOG 0535)","volume":"4","author":"Lancet","year":"2020","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of Acute Promyelocytic Leukemia: Recommendations from an Expert Panel on Behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2022.866746","article-title":"The Therapeutic Potential of Anticoagulation in Organ Fibrosis","volume":"9","author":"Oh","year":"2022","journal-title":"Front. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"106174","DOI":"10.1016\/j.leukres.2019.106174","article-title":"Fibrinogen Consumption and Use of Heparin Are Risk Factors for Delayed Bleeding during Acute Promyelocytic Leukemia Induction","volume":"83","author":"Hambley","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/14728222.2016.1086750","article-title":"Thrombomodulin as an Intravascular Safeguard against Inflammatory and Thrombotic Diseases","volume":"20","author":"Ito","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13054-019-2552-0","article-title":"Thrombomodulin in Disseminated Intravascular Coagulation and Other Critical Conditions\u2014A Multi-Faceted Anticoagulant Protein with Therapeutic Potential","volume":"23","author":"Ito","year":"2019","journal-title":"Crit. Care"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and Safety of Recombinant Human Soluble Thrombomodulin (ART-123) in Disseminated Intravascular Coagulation: Results of a Phase III, Randomized, Double-Blind Clinical Trial","volume":"5","author":"Saito","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0049-3848(10)70013-X","article-title":"Open Issues on Bleeding and Thrombosis in Acute Promyelocytic Leukemia","volume":"125","author":"Sanz","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0609.2004.00237.x","article-title":"Effective Treatment of Life-Threatening Bleeding with Recombinant Activated Factor VII in a Patient with Acute Promyelocytic Leukaemia","volume":"72","author":"Zver","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"ref_136","first-page":"410","article-title":"Analysis of clinical efficacy of recombinant activated factor VII on bleeding in patients with hematologic disorders","volume":"38","author":"Liu","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/10428194.2011.605189","article-title":"Cerebral Hemorrhage Treated with NovoSeven in Acute Promyelocytic Leukemia","volume":"53","author":"Nosari","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1006221","article-title":"Safety of Recombinant Activated Factor VII in Randomized Clinical Trials","volume":"363","author":"Levi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1213\/ANE.0000000000001947","article-title":"Recombinant Factor VIIa Is Associated With Increased Thrombotic Complications in Pediatric Cardiac Surgery Patients","volume":"124","author":"Downey","year":"2017","journal-title":"Anesth. Analg."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","article-title":"High-Dose Antithrombin III in Severe SepsisA Randomized Controlled Trial","volume":"286","author":"Warren","year":"2001","journal-title":"JAMA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s001340050642","article-title":"Antithrombin III in Patients with Severe Sepsis","volume":"24","author":"Eisele","year":"1998","journal-title":"Intensive Care Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1016\/j.febslet.2005.03.001","article-title":"The Anticoagulant Protein C Pathway","volume":"579","author":"Villoutreix","year":"2005","journal-title":"FEBS Lett."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40560-014-0050-7","article-title":"Thrombomodulin\/Activated Protein C System in Septic Disseminated Intravascular Coagulation","volume":"3","author":"Ikezoe","year":"2015","journal-title":"J. Intensiv. Care"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3477\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:05:24Z","timestamp":1760126724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":144,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15133477"],"URL":"https:\/\/doi.org\/10.3390\/cancers15133477","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]}}}